Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veligrotug in Non-responders with Thyroid Eye Disease
NCT06179875Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of veligrotug in thyroid eye disease (TED), sponsored by Viridian Therapeutics. Started Jan 2024; status: completed.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06179875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179875.